首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Oncoimmunology

缩写:ONCOIMMUNOLOGY

ISSN:2162-402X

e-ISSN:2162-402X

IF/分区:6.3/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引892
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Hannelore Ceuppens,Kirsten De Ridder,Thomas Ertveldt et al. Hannelore Ceuppens et al.
α- and β--emitting radionuclides targeting human fibroblast activation protein-α (hFAP) are under investigation for cancer therapy. In prior work, analysis of the tumor microenvironment 24 h after therapy completion indicated therapy-ind...
Parisa Nikeghbal,Danielle Burke,Dalet Armijo et al. Parisa Nikeghbal et al.
While most ovarian cancer (OC) patients respond to front-line platinum/taxane chemotherapy and surgical debulking, the majority will develop platinum-resistance and recur. Our study investigated how tumor-associated macrophages (TAMs) withi...
Yu-Chen Shi,Qingling An,Na Tang et al. Yu-Chen Shi et al.
Immunotherapy has demonstrated potential in treating various malignant tumors, but its efficacy in pancreatic cancer (PC) remains limited, possibly due to the dense stromal components and immunosuppressive microenvironment of PC. Focal adhe...
Henna Karjalainen,Jouni Härkönen,Päivi Sirniö et al. Henna Karjalainen et al.
Gamma-delta T cells are a subset of T cells that have features of both innate and adaptive immunity. Their role in cancer remains controversial, since both anti- and protumor functions have been reported. We aimed to shed light on the disti...
Karys M Hildebrand,Kurt N Hildebrand,Carolina Salazar Arcila et al. Karys M Hildebrand et al.
Soft tissue sarcomas (STS) are aggressive high-fatality cancers that affect children and adults. Most STS subtypes harbor an immunosuppressive tumor microenvironment (TME) and respond poorly to immunotherapy. Therapies capable of dismantlin...
Djamila Chemlal,Camille Pochard,Valentin Jacquier et al. Djamila Chemlal et al.
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prosp...
Claudia Galassi,Giulia Petroni,Simon R V Knott et al. Claudia Galassi et al.
CDK4/6 inhibitors are central to the clinical management of HR+HER2- breast cancer. We have recently demonstrated that immunosuppressive, IL17-secreting γδ T cells recruited to the tumor microenvironment by a CCL2-dependent mechanism upon...
Oliver Kepp,Guido Kroemer Oliver Kepp
HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome a...
Annina Kurzay,Sara Fresnillo Saló,Anne Rahbech et al. Annina Kurzay et al.
Cancer immunotherapy predominantly targets CD8 T cells, but recent evidence highlights the importance of CD4 T cells in adoptive cell therapy (ACT). The TAM receptor MerTK regulates immune responses and has been shown to provide costimulato...